Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9172)	9/18/2003 11:05:38 AM
From: Biomaven	Read Replies (1) of 52153

I don't normally talk about BB stocks (except KDUS), but I do own some shares in POTP - Point Therapeutics (a SEPR spin-off then reverse merger). They just had a shareholder meeting and update, which I missed, but judging by the price action it looks like someone liked what they saw. Replay will be available here: corporate-ir.net They have a small molecule challenger to Neupogen, and so they would be a 20 bagger or better in the unlikely event their molecule succeeds. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next